Brokers

Brokers Issue Forecasts for Rani Therapeutics Holdings, Inc.’s FY2023 Earnings (NASDAQ:RANI)


Rani Therapeutics Holdings, Inc. (NASDAQ:RANIGet Rating) – Research analysts at Cantor Fitzgerald issued their FY2023 earnings per share (EPS) estimates for shares of Rani Therapeutics in a research report issued on Monday, June 6th. Cantor Fitzgerald analyst B. Folkes forecasts that the company will earn ($1.40) per share for the year.

Rani Therapeutics (NASDAQ:RANIGet Rating) last posted its earnings results on Wednesday, May 11th. The company reported ($0.29) earnings per share for the quarter, topping the consensus estimate of ($1.00) by $0.71.

Separately, Zacks Investment Research upgraded shares of Rani Therapeutics from a “hold” rating to a “buy” rating and set a $13.00 price objective for the company in a research report on Thursday, June 2nd. Six investment analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has an average rating of “Buy” and an average price target of $21.40.

RANI opened at $9.32 on Thursday. The firm has a 50-day moving average price of $11.91 and a 200-day moving average price of $16.06. Rani Therapeutics has a twelve month low of $9.10 and a twelve month high of $36.27.

A number of institutional investors have recently made changes to their positions in the business. United Services Automobile Association bought a new stake in Rani Therapeutics during the first quarter valued at approximately $6,498,000. Vanguard Group Inc. lifted its position in Rani Therapeutics by 1.6% during the first quarter. Vanguard Group Inc. now owns 290,107 shares of the company’s stock valued at $3,916,000 after purchasing an additional 4,561 shares during the last quarter. BlackRock Inc. lifted its position in Rani Therapeutics by 37.7% during the first quarter. BlackRock Inc. now owns 157,374 shares of the company’s stock valued at $2,125,000 after purchasing an additional 43,076 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Rani Therapeutics by 192.1% in the 4th quarter. Geode Capital Management LLC now owns 63,217 shares of the company’s stock worth $1,033,000 after acquiring an additional 41,578 shares during the last quarter. Finally, Lasry Marc bought a new stake in shares of Rani Therapeutics in the 1st quarter worth approximately $848,000. Institutional investors and hedge funds own 2.31% of the company’s stock.

Rani Therapeutics Company Profile (Get Rating)

Rani Therapeutics Holdings, Inc operates as a clinical stage biotherapeutics company that develops orally administered biologics. The company develops the RaniPill capsule, a platform that is intended to replace subcutaneous or IV injection of biologics with oral dosing. Its product pipeline includes RT-101, an octreotide, which has completed Phase I clinical trial for the treatment of neuroendocrine tumors and acromegaly; RT-105, an anti-TNF-alpha antibody to treat psoriatic arthritis; RT-102, a parathyroid hormone that is in preclinical studies for the treatment of osteoporosis; RT-109, a human growth hormone to treat growth hormone deficiency; RT-110, a parathyroid hormone for the treatment of hypoparathyroidism; and RT-106, a basal insulin for the treatment of type 2 diabetes.

Further Reading



Receive News & Ratings for Rani Therapeutics Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Rani Therapeutics and related companies with MarketBeat.com’s FREE daily email newsletter.

Source link

Related Articles

Leave a Reply

Your email address will not be published.

Back to top button
SUBSCRIBE TO OUR NEWSLETTER

Get our latest downloads and information first. Complete the form below to subscribe to our weekly newsletter.